Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

Slides:



Advertisements
Similar presentations
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
Advertisements

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Product Pipeline Neratinib across the breast cancer therapy spectrum
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Phase III PlanB Final Analysis: Adjuvant TC vs ECT in Pts With High-Risk HER2-Negative Early Breast Cancer CCO Independent Conference Highlights* of the.
Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;
CCO Independent Conference Highlights
Adjuvant Therapy for HER2+ Breast Cancer Dana-Farber Cancer Institute
Intention-to-treat population
Addressing the Challenges in Primary and Secondary Stroke Prevention
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Product Pipeline Neratinib across the breast cancer therapy spectrum
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.
Current Dyslipidemia Management Guidelines Residual Risk.
Neoadjuvant Therapy for HER2-Positive Breast Cancer
A Paradigm Shift in PAH.
New Horizons in the Management of Advanced Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Her2-positive breast cancer: updating current best practice
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
The Nurse View.
سرطان الثدي Breast Cancer
Overall Program Goals. Overall Program Goals Current Approaches.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Moving Evidence into Practice: Breast Cancer Highlights From Chicago
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Managing gBRCA-Positive Metastatic Breast Cancer
Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Optimizing Neoadjuvant Treatment for Primary Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer:
Drug-Coated Balloons:
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
The Road to Quality Improvement in HER2-Positive Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
New Paradigms in HR-Positive Advanced Breast Cancer
Product Pipeline Neratinib across the breast cancer therapy spectrum
Preparing for Checkpoint Inhibitors in Breast Cancer
Clinical Challenges and Updates in Managing Seizure Clusters
An Unmet Need.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 
CDK4/6 Inhibitors.
The Nurse View: Spotlight on EGFR-Mutated NSCLC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Clinical Focus.
Immune Checkpoint Inhibitors in Lung Cancer
Presentation transcript:

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

ASCO-CAP Recommendations For HER2 Testing in Breast Cancer

Criteria For Reporting HER2 Test Results as Positive

Criteria for Reporting HER2 Test Results as Negative

Criteria for Reporting Equivocal Results

Criteria for Reporting Indeterminate Results

NSABP B-47 Findings

ASCO Recommendations for Adjuvant Therapy for HER2-Positive Breast Cancer

ASCO Recommendations for Adjuvant Therapy for HER2-Positive Breast Cancer (cont)

APT Trial

Updated Analysis of APT Trial

APHINITY Trial

APHINITY Results

Invasive DFS at 3 Years

APHINITY Safety Data

Most Common Grade ≥ 3 AEs

NeoSphere Trial

NeoSphere Results

ExteNET Trial

ExteNET Trial Amendments

Baseline Characteristics

ExteNET Results

ExteNET: AEs

Preventing Neratinib-Associated Diarrhea: The CONTROL Trial

CONTROL: Results of Interim Analysis Reported at 2017 AACR

CONTROL: Results of Interim Analysis Reported at 2017 AACR (cont)

Take-Home Messages

Take-Home Messages (cont)

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.